trending Market Intelligence /marketintelligence/en/news-insights/trending/IpqE7sNwbV1ozIU1CDlpJw2 content esgSubNav
In This List

TWi Pharmaceuticals chairman offers to take company private

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


TWi Pharmaceuticals chairman offers to take company private

TWi Pharmaceuticals Inc. founder and Chairman Chen Chih-ming plans to take the company private, the Taipei Times reported, citing a regulatory filing.

The going-private deal, which will be done through a tender offer and a share swap, is intended to strengthen the company's financial structure and adjust its product development strategy, according to the report.

Chen offered to acquire 52.44 million shares, representing 43.57% of the company's issued shares, at NT$72 apiece in an open market transaction using one of his personal investment entities. He already owns a 3.62% stake in the company, a developer of generic drugs.

The tender offer, which launched March 22, requires a minimum purchase of 6.02 million shares, or 5% of the Taipei-based company's issued shares. The tender offer is open for acceptance until April 15.

Upon completion of the tender offer, Chen's investment entity will swap shares at a one-to-one exchange ratio to acquire 100% of TWi Pharmaceuticals. The investment entity plans to apply for the delisting of TWi's shares from the Taipei Exchange in the third quarter.

TWi's board will initiate a strategic review process before approving Chen's buyout offer.

KGI Securities Co. is helping TWi Pharmaceuticals manage the offer.

As of March 22, US$1 was equivalent to NT$30.89.